The ID3 Knockout TE1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the TE1 human esophageal squamous cell carcinoma line. This loss-of-function model, generated by CRISPR/Cas9-mediated gene disruption, enables investigation of ID3-dependent regulatory networks without clonal selection biases, preserving genetic heterogeneity akin to tumor cell populations.
TE1 is a widely utilized model of esophageal squamous cell carcinoma, originating from a poorly differentiated primary tumor with tumorigenic properties. The cell line retains key molecular alterations in growth factor signaling and cell cycle control, making it a relevant host for studying esophageal cancer pathogenesis, invasion, and therapeutic responses.
ID3 encodes a dominant-negative inhibitor of basic helix-loop-helix (bHLH) transcription factors, including E2A (TCF3), MYOD, and ITF-2, which it sequesters into inactive heterodimers. ID3 integrates signals from TGF-beta/BMP (via SMAD2/3/4 and BMPR1/2), Notch (Notch1), PI3K/AKT, and Wnt/beta-catenin pathways. Its expression is controlled by upstream regulators such as MYC, NF-kB, SMADs, TCF/LEF, and EGR1, and it modulates downstream targets like p21CIP1, p15INK4b, and BCL2 family members. Disruption of ID3 relieves bHLH repression, restoring E-box-mediated transcription and potentially sensitizing cells to TGF-beta/BMP-induced growth inhibition.
In esophageal squamous cell carcinoma, ID3 can act as either tumor suppressor or oncogene depending on cellular context. ID3 knockout in TE1 cells may derepress bHLH-driven programs affecting proliferation, apoptosis, and differentiation, offering a model to examine how ID3 loss influences stemness, epithelial-mesenchymal transition, and response to microenvironmental cues. This system is especially useful for dissecting TGF-beta/BMP-mediated tumor suppression, which is frequently dysregulated in esophageal cancer.
Applications include cell viability assays (MTT), cell cycle analysis and apoptosis detection by flow cytometry, Transwell migration/invasion assays, and molecular profiling via RT-qPCR and Western blotting for ID3, SMAD2/3, and E-box targets. Luciferase reporter assays quantify bHLH transcriptional activity. These tools facilitate research into esophageal cancer biology, ID3-mediated transcriptional control, drug sensitivity, and TGF-beta/BMP signaling. For further inquiries, contact Ascent Research.
